Trials / Recruiting
RecruitingNCT06094556
An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors
A Multicenter, Open Phase I Clinical Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of SHR-1826 for Injection in Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 240 (estimated)
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is an open, multi-center, dose-escalation/dose-expansion/efficacy expansion phase I clinical study to evaluate the tolerability, safety, PK, and immunogenicity of SHR-1826 in patients with advanced malignant solid tumors, and to preliminatively observe its antitumor efficacy. The whole study was divided into three stages: dose increment, dose extension and therapeutic effect extension.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1826 | dose is calculated based on the subjects' baseline weight. |
Timeline
- Start date
- 2023-12-25
- Primary completion
- 2027-06-30
- Completion
- 2027-07-31
- First posted
- 2023-10-23
- Last updated
- 2025-04-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06094556. Inclusion in this directory is not an endorsement.